PraxisPro Raises $6M Seed Round to Transform Life Sciences with AI for Commercial Intelligence

HOUSTON--(BUSINESS WIRE)--PraxisPro, a data intelligence company rebuilding the fractured state of Life Sciences, today announced the close of its oversubscribed $6M seed round led by AlleyCorp. Additional investors in the round included Flybridge, South Loop Ventures, Zeal Capital Partners, True Ventures, Techstars, Alumni Ventures, and Daring Ventures.

Life Sciences organizations rely on fragmented, incomplete, and often undocumented data with their customers to make critical commercial decisions. This often creates avoidable compliance risks and missed opportunities to improve patient outcomes. PraxisPro is addressing this challenge by surfacing previously inaccessible datasets through its application of purpose-built Small Language Models (SLM) and AI Agents, designed specifically for therapeutic areas and disease states.

Through its Learning Experience Platform (LXP), which leverages small language models and AI agents, PraxisPro gives Life Science organizations the ability to address rising training costs driven by regulation, declining HCP engagement, and the lack of continuity between pre-call planning, post-call insight, and out-of-territory education. The result is a clearer picture of what’s happening in the field and how teams can improve without adding operational burden.

As indicated by the world's largest LLM companies, Life Sciences organizations are hungry for the ability to improve patient outcomes by creating a more reliable, governed approach to generating commercial intelligence while reducing cost, complexity, and compliance risk.

By serving as the commercial intelligence backbone across commercial, medical, and compliance functions, PraxisPro’s industry-specific AI models for therapeutic areas and disease states form the foundation of a new standard of commercial intelligence, one that enables disciplined execution at scale while allowing Life Sciences organizations to focus on what matters most: improving patient outcomes.

“As a former sales professional, training leader, and commercial operator, we’re building the products I wish I had in every role I held,” said Cam Badger, Founder and CEO of PraxisPro. “By using curated, purpose-built SLMs, we’re helping Life Sciences teams generate the new data and insight they need to operate better, and ultimately make a greater difference for patients who rely on them.”

“PraxisPro is applying AI in a way that is truly native to Life Sciences. Purpose-built models, governed data, and a deep understanding of real commercial workflows make this platform and this team uniquely positioned to lead the category,” said Omar Njie, Principal at AlleyCorp.

PraxisPro plans to invest the new funding into improving the core platform, including streamlined therapeutic area and disease state SLMs, an enhanced mobile experience, self-service experiences, and growing the team to support the growing number of customers.

PraxisPro’s LXP is currently commercially available. Interested companies can reach PraxisPro at [e-mail] or visit www.praxispro.ai